Synovics Pharmaceuticals Announces Continued Growth of Customer Rel... (se companies. With thenew product develo...)

Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships

Date:6/18/2008

se companies. With the new product development and manufacturing capacity we are acquiring through our growing strategic relationships in India, we believe we have a very timely opportunity to build our OTC private label business. The Company's India Front-End strategy has the prospect to deliver high quality, new products to our customers while keeping our pricing most competitive."

About Synovics:

Synovics is a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of prescription and over-the-counter (OTC) drugs. The Company has two operating subsidiaries, Kirk Pharmaceuticals, LLC and ANDAPharm, LLC, which manufacture and sell OTC and prescription private label drugs respectively, and Synovics Labs, Inc. a drug development subsidiary that is pursuing generic drug opportunities. Synovics employs approximately 150 people in its Ft. Lauderdale facility of 80,000. Sq Ft. The Company manufactures drug products in specialized containment suites including hormonal prescription drugs and under its Drug Enforcement Administration (DEA) licenses. The Company has a Front-End strategy based business plan - a strategy of sourcing lowest cost, highly competitive generic drug products from India, marketed to the Company's U.S. customers through its Ft. Lauderdale operations. Synovics' previously announced strategic partnerships with Maneesh Pharmaceuticals, LTD and Harcharan ("Harry") Singh of Glopec International that represent the Company's cornerstone for its Front-End India strategy. The Company believes cost is the single most important element in the generic drug industry and it is reaching out through its strategic partners to source products and services from a variety of smaller and quite willing independent Indian pharmaceutical companies that have these assets, but also have limited means of accessing the U.S. market.

"Safe Harbor" statements under the Private Securities Litigation Reform Act of 1995: Ex
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs

Post Your Comments:

Synovics Pharmaceuticals Announces Continued Growth of Customer Rel...(se companies. With thenew product develo...)